Pandia Health Prescribing Data and Outcomes Signals: What the Evidence Actually Shows

What Is Pandia Health and How Does Its Model Work?

Pandia Health is a direct-to-consumer telehealth company that prescribes FDA-approved hormonal contraceptives and menopausal hormone therapy (MHT) through asynchronous and synchronous video visits. It was founded by Dr. Sophia Yen, a Stanford-trained clinical associate professor, who positioned it specifically as a women's health platform rather than a general telehealth marketplace.

The cash-pay model means patients pay out of pocket. Consultations typically run $25 to $40 per visit, with medication costs layered on top. Because no insurance billing is involved, there is no insurance-derived claims dataset that independent researchers can audit.

How Prescribing Decisions Are Made

All prescriptions are written by licensed physicians. The platform does not allow nurse practitioners or physician assistants to independently prescribe in states where that would require physician oversight, though state-law variability means the actual supervision structure differs by jurisdiction.

Contraceptive selection follows the U.S. Medical Eligibility Criteria for Contraceptive Use (US MEC), published by the CDC. The 2024 update to the US MEC classifies combined hormonal contraceptives as Category 1 (no restriction) for healthy, non-smoking women under 35 and Category 3 or 4 for women with certain cardiovascular risk factors. [1]

Menopause prescribing at Pandia Health generally centers on low-dose estradiol (oral, patch, or gel) with or without progesterone. The 2022 Menopause Society (formerly NAMS) hormone therapy position statement supports individualized MHT for symptomatic women under 60 or within 10 years of menopause onset in the absence of contraindications. [2]

What "Outcomes Signals" Are Available

The phrase "prescribing data and outcomes signals" is significant. Pandia Health has not published a peer-reviewed cohort study or a publicly available quality report with actual adherence, side-effect, or discontinuation rates. What can be assessed indirectly includes:

• Patient-reported reviews on Trustpilot, Google, and Healthgrades
• Better Business Bureau complaint logs
• State pharmacy board and medical board disciplinary records
• FDA Warning Letter database entries (or the absence thereof)

None of these are outcomes data in a clinical sense. They are safety signals.

Prescribing Patterns: What the Evidence Supports

Contraceptive Prescribing Alignment With Guidelines

Hormonal contraceptives prescribed via telehealth produce comparable effectiveness and safety to those prescribed in-office when guideline-concordant screening is performed. A 2022 JAMA Internal Medicine analysis of telehealth contraception visits found that remote prescribing of combined oral contraceptives was associated with comparable continuation rates at 6 months when blood-pressure screening was conducted, though the study could not verify in-person BP measurement compliance. [3]

The CDC's US MEC is the standard that all U.S. Prescribers, including telehealth providers, are expected to apply. Pandia Health's published intake form asks about migraine with aura, hypertension, smoking history, and prior VTE, which are the four highest-risk screening criteria for combined hormonal contraceptives. That alignment is a positive signal, though patient-reported screening is not the same as clinician-measured vital signs.

The absolute risk of venous thromboembolism (VTE) on combined oral contraceptives is approximately 3 to 9 events per 10,000 women-years, compared to 1 to 5 per 10,000 in non-users, as reported in a 2014 BMJ meta-analysis of 26 studies covering more than 3 million women-years of observation. [4] Telehealth prescribing does not inherently change this risk, but it shifts who bears responsibility for identifying contraindications.

Menopause Hormone Therapy Prescribing

The Women's Health Initiative (WHI) originally published in JAMA (N=16,608 for the estrogen-plus-progestin arm) showed increased breast cancer risk with conjugated equine estrogen plus medroxyprogesterone acetate (CEE/MPA) over 5.6 years, but subsequent re-analyses have clarified that younger, recently menopausal women face a materially different risk profile than the older WHI cohort (average age 63). [5]

Pandia Health's prescribing leans toward bioidentical estradiol and micronized progesterone rather than CEE/MPA. Micronized progesterone (Prometrium 100 mg or 200 mg) carries a more favorable thrombotic risk signal than synthetic progestins, based on the E3N cohort study (N=80,377 French women) showing no elevated VTE risk vs. A relative risk of 3.5 to 4.0 for synthetic progestins. [6]

That is a clinically meaningful distinction, and it suggests Pandia Health's formulary choices are directionally consistent with current evidence.

Is Pandia Health Legitimate?

Pandia Health operates legally. That is the direct answer.

Regulatory Standing

The company holds valid pharmacy partner agreements with licensed U.S. Pharmacies for dispensing. LegitScript, the verification body used by Google and major payment processors to vet online pharmacies and telehealth providers, requires that platforms demonstrate state-licensed prescribers, valid prescriber-patient relationships, and dispensing through licensed pharmacies. Pandia Health maintains that certification.

The FDA's Warning Letter database, searchable at fda.gov, shows no public enforcement action against Pandia Health as of January 2025. [7]

The California Medical Board (Pandia Health's home state) shows no disciplinary actions against the company's founding physicians in its publicly searchable license verification tool.

BBB and Consumer Complaint Profile

The BBB profile for Pandia Health is present but the company is not BBB-accredited. The complaint volume in the BBB database is low, in the single digits as of this review, which for a multi-year telehealth company with tens of thousands of patients is not alarming. The nature of the complaints logged centers on billing disputes and prescription delays rather than clinical harm allegations.

Patient reviews on Trustpilot skew positive (averaging above 4 out of 5 stars across more than 500 reviews as of early 2025), though self-selected review platforms systematically over-represent satisfied users and cannot substitute for audited outcome data.

Complaints and Known Limitations

What Patients Complain About

The pattern in public complaint data across BBB, Trustpilot, and Reddit threads points to three recurring issues:

1. Prescription delays at the pharmacy level. Because Pandia Health uses third-party pharmacy networks rather than an in-house dispensary, fulfillment speed depends on the contracted pharmacy's stock and the patient's state.
2. Customer service response times. Several reviewers describe difficulty reaching support after submission of intake forms, especially around weekends.
3. Insurance reimbursement confusion. The platform is cash-pay. Some patients report expecting insurance coverage and then receiving surprise out-of-pocket bills.

None of these complaints, as documented, constitute clinical-safety concerns.

What the Platform Does Not Offer

Pandia Health does not prescribe:

• GLP-1 receptor agonists (semaglutide, tirzepatide)
• Testosterone or DHEA for androgen insufficiency
• Thyroid medications

Women seeking a broader hormonal workup or treatment of conditions like PCOS beyond contraceptive management will need a different provider. The platform's focused scope is both a strength (it does one category well) and a structural limitation.

Data Privacy Considerations

Telehealth platforms handling protected health information (PHI) are covered entities or business associates under HIPAA. Pandia Health's privacy policy states standard HIPAA-compliant data handling. There have been no FTC actions or HHS Office for Civil Rights breach notifications publicly linked to Pandia Health in the searchable HHS breach portal as of January 2025. [8]

The 2023 FTC enforcement action against GoodRx for sharing health data with Facebook and Google without consent is a relevant sector precedent. That case resulted in a $1.5 million civil penalty and a prohibition order. [9] Patients using any telehealth platform should review whether pixel-tracking or third-party analytics tools are deployed on intake forms.

Outcomes Signals From the Broader Telehealth Contraception Literature

Because Pandia Health has no published trial data, the best proxy for expected outcomes comes from the peer-reviewed telehealth contraception literature.

Continuation Rates

A 2021 study in Contraception (N=982 patients at an online contraception clinic) found a 12-month continuation rate of 68% for combined oral contraceptives prescribed via telehealth, comparable to the 66% to 72% range reported in office-based settings in a Cochrane review of 18 trials. [10, 11]

Side-Effect Reporting in Telehealth Contexts

The same 2021 Contraception study found that 14% of patients discontinued due to side effects (primarily breakthrough bleeding and mood changes) and 11% discontinued due to preference changes. These figures align with in-office prescribing data, supporting the argument that the telehealth delivery channel itself does not materially alter the pharmacological side-effect profile of the medications.

Menopause Quality-of-Life Endpoints

The NAMS 2022 position statement cites Level I evidence that MHT produces statistically significant reductions in vasomotor symptom frequency and severity, with effect sizes of 75% reduction in hot flash frequency vs. Placebo in multiple RCTs. [2] Patients receiving estradiol via any prescriber, telehealth or in-person, should expect similar symptom relief if the dose is appropriately titrated.

The table below shows a practical decision framework for evaluating whether Pandia Health is the right telehealth platform for a given patient's hormonal needs.

| Patient Profile | Pandia Health Appropriate? | Reason | |---|---|---| | Healthy, non-smoking woman <35, wants pill/patch/ring | Yes | Scope match, guideline-concordant intake | | Perimenopausal woman <60, symptomatic, no contraindications | Yes | MHT formulary aligns with NAMS guidance | | Woman with migraine with aura seeking COC | No | US MEC Category 4; COC contraindicated | | Woman wanting PCOS metabolic workup plus weight management | No | Outside platform scope | | Woman needing testosterone or DHEA | No | Not on formulary | | Woman with prior VTE seeking any estrogen | No | Requires in-person thrombophilia workup first |

How Pandia Health Compares to In-Person Prescribing Standards

No telehealth company operates outside the same FDA-approved drug universe or outside the same clinical guidelines that govern in-person prescribing. The drugs are identical. The guidelines are identical. What differs is the screening process.

The ACOG Committee Opinion No. 761 states that telemedicine is appropriate for contraceptive counseling and prescribing when adequate history-taking can be performed and when the patient is informed about when in-person evaluation is needed. [12] ACOG explicitly endorses pharmacist and telehealth prescribing of hormonal contraceptives as an access-expansion strategy.

The real question is not whether Pandia Health is "legitimate." The question is whether asynchronous text-based intake screens adequately substitute for clinical examination in identifying the subset of patients who should not receive combined estrogen-progestin therapy. The published literature suggests that self-reported contraindications, when systematically collected, capture most high-risk patients, but "most" is not "all."

A 2019 Annals of Internal Medicine study found that blood-pressure readings taken at home and self-reported to telehealth providers showed acceptable concordance with clinic measurements in a general primary-care population, though the contraceptive-specific subgroup was not separately analyzed. [13]

What Would Make the Evidence Base Stronger

The gap in Pandia Health's public evidence profile is the absence of a prospectively collected outcomes dataset. Specific data that would meaningfully change the confidence level in this review:

• A published or audited cohort showing VTE incidence rates per 10,000 patient-years in their prescribed population vs. Expected background rates
• Discontinuation rates at 6 and 12 months, broken out by formulation
• Adverse event reporting rates and how they compare to the FDA's MedWatch signal database for the same drug classes
• An audit of what percentage of intake-form contraindication screens result in prescription refusal vs. Approval

Until that data exists, the prescribing model can be evaluated as guideline-concordant in structure. Clinical outcome equivalence with in-person care remains an extrapolation from the broader telehealth contraception literature, not from Pandia Health's own data.

The FDA's MedWatch database (fda.gov/safety/medwatch) allows any patient or clinician to report adverse events from any FDA-regulated drug. [14] Patients who experience suspected drug-related complications through any telehealth prescriber, including Pandia Health, should file a MedWatch report.